AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18833115 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with additional dosage of levodopa/DDC inhibitor
Number of subjects: 0
Study 15684256 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) injections (40,000 UI/week subcutaneously until Ht of 40%)
Number of subjects: 93
Study 15684256 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood donation (ABD) (RBC pack collected weekly as long as Ht was above 33%)
Number of subjects: 93
Study 15684256 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of RBC production
Number of subjects: 93
Study 15114293 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. Dextran-40 infusion (Group I, n = 48)
Number of subjects: 69
Study 15114293 — intervention group
Group type: COMPARATOR
Intervention: i.v. albumin infusion (Group II, n = 48)
Number of subjects: 69
Study 10798009 — intervention group
Group type: EXPERIMENTAL
Intervention: pH measurement
Number of subjects: 0
Study 10798009 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific gravity measurement
Number of subjects: 0
Study 10798009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar excretion measurement
Number of subjects: 0
Study 10798009 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein profile on SDS-PAGE
Number of subjects: 0
Study 7597269 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer
Number of subjects: 57
Study 7597269 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nebulized salbutamol and ipratropium bromide
Number of subjects: 57
Study 7597269 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilator therapy
Number of subjects: 57
Study 2035777 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms of fentanyl administered prophylactically by the epidural route
Number of subjects: 0
Study 7369086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (10 hours)
Number of subjects: 24
Study 7369086 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal body-part identification training (10 hours)
Number of subjects: 24
Study 7369086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study 31721905 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% compound lidocaine cream (0.2 g/cm2)
Number of subjects: 60
Study 31721905 — intervention group
Group type: COMPARATOR
Intervention: Morphine group (10 mg tablet)
Number of subjects: 60
Study 27957595 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 28
Study 25472578 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 993
Study 25472578 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 993
Study 23429575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined optical and atropine treatment (COAT)
Number of subjects: 5
Study 21829015 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 1,000 U/ml (group 2)
Number of subjects: 184
Study 21829015 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5,000 U/ml (group 1)
Number of subjects: 184
Study 21829015 — intervention group
Group type: COMPARATOR
Intervention: Both groups (1,000 U/ml and 5,000 U/ml)
Number of subjects: 184
Study 19409095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (computer-generated feedback, educational outreach, and dedicated support)
Number of subjects: 72
Study 19409095 — intervention group
Group type: COMPARATOR
Intervention: Computer-generated feedback (simple feedback)
Number of subjects: 72
Study 17728047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration (50 mg)
Number of subjects: 0
Study 17728047 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15170922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 75 mg/day
Number of subjects: 472
Study 15170922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 150 mg/day
Number of subjects: 472
Study 15170922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (all dosages)
Number of subjects: 472
Study 15170922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 11720073 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby wipes
Number of subjects: 162
Study 11720073 — intervention group
Group type: COMPARATOR
Intervention: Water and cleansing material
Number of subjects: 162
Study 9734541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 168
Study 9734541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 8069884 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate-based toothpaste with 0.3% triclosan
Number of subjects: 20
Study 8069884 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate-based toothpaste without triclosan
Number of subjects: 20
Study 8069884 — intervention group
Group type: COMPARATOR
Intervention: Alumina-based toothpaste
Number of subjects: 20
Study 8069884 — intervention group
Group type: COMPARATOR
Intervention: Silica-based toothpaste
Number of subjects: 20
Study 1975426 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of pentamidine every two weeks
Number of subjects: 408
Study 1975426 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of pentamidine every two weeks
Number of subjects: 408
Study 1975426 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of pentamidine every four weeks
Number of subjects: 408
Study 1975426 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 408
Study 159510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 microgram) administered as two puffs from a metered dose inhaler four times a day for one week (regular use)
Number of subjects: 12
Study 159510 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ipratropium bromide (40 microgram) given 2.5 hours before the test
Number of subjects: 12
Study 159510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (propellants only) administered four times a day for one week (regular use)
Number of subjects: 12
Study 159510 — intervention group
Group type: COMPARATOR
Intervention: Control period with no treatment
Number of subjects: 12
Study 31684916 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assessment and evaluation protocol for HA implementation
Number of subjects: 241
Study 31684916 — intervention group
Group type: COMPARATOR
Intervention: Ordinary routines applied in control group
Number of subjects: 241
Study 27676226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplant recipients requiring reintubation
Number of subjects: 201
Study 27676226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplant recipients discharged to care facilities
Number of subjects: 201
Study 27676226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplant recipients overall
Number of subjects: 201
Study 27676226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplant recipients with lower capacity to engage in self-care
Number of subjects: 201
Study 27676226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplant recipients older age
Number of subjects: 201
Study 27676226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplant recipients returning to the intensive care unit
Number of subjects: 201
Study 27676226 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirty-day readmission
Number of subjects: 201
Study 25554797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise before breakfast (AM)
Number of subjects: 9
Study 25554797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after lunch (PM)
Number of subjects: 9
Study 25554797 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions of exercise (AM/PM)
Number of subjects: 9
Study 25554797 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary day)
Number of subjects: 9
Study 24018221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sessions for alcohol use
Number of subjects: 120
Study 24018221 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence goal
Number of subjects: 120
Study 24018221 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation goal
Number of subjects: 120
Study 24018221 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern of relatives, friends, or doctors
Number of subjects: 120
Study 24018221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care patients
Number of subjects: 120
Study 24018221 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up goal change
Number of subjects: 120
Study 21400652 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer (BP) sirolimus‐eluting stent
Number of subjects: 2016
Study 21400652 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer (PP) sirolimus/everolimus‐eluting stent
Number of subjects: 2016
Study 19360536 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwestern Prevention Project (MPP) program
Number of subjects: 961
Study 19360536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 961
Study 17597038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 100
Study 17597038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100
Study 17597038 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 100
Study 17597038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 100
Study 17597038 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 15074013 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive regimen after surgery (n = 16)
Number of subjects: 29
Study 15074013 — intervention group
Group type: COMPARATOR
Intervention: No immunosuppression (n = 13)
Number of subjects: 29
Study 11563899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan, 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally, as an adjunct to compression therapy and topical wound care.
Number of subjects: 183
Study 11563899 — intervention group
Group type: COMPARATOR
Intervention: Placebo, as an adjunct to compression therapy and topical wound care.
Number of subjects: 183
Study 11563899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 183
Study 11563899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 9758288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily for 5 days with 200 mg trovafloxacin once daily from day 3-5
Number of subjects: 12
Study 9758288 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days with 200 mg trovafloxacin once daily from day 3-5
Number of subjects: 12
Study 7823272 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of metronidazole gel
Number of subjects: 12
Study 7823272 — intervention group
Group type: COMPARATOR
Intervention: Control (no metronidazole application)
Number of subjects: 12
Study 3245293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (3 administrations of microgranules)
Number of subjects: 18
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported child height
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported child weight
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated body mass index from parent-reported data
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported child height and weight accuracy at baseline
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported child height and weight accuracy after 12-week intervention
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater agreement of child body mass index category
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight category accuracy from parent-reported data
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental age influence on reporting accuracy
Number of subjects: 42
Study 31538954 — intervention group
Group type: EXPERIMENTAL
Intervention: Child age influence on reporting accuracy
Number of subjects: 42
Study 28734705 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency based Stepwise Endovascular Curricular Training (PROSPECT)
Number of subjects: 32
Study 28734705 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning and simulation training (PROSPECT)
Number of subjects: 32
Study 28734705 — intervention group
Group type: COMPARATOR
Intervention: E-learning only
Number of subjects: 32
Study 28734705 — intervention group
Group type: COMPARATOR
Intervention: Traditional education (Control)
Number of subjects: 32
Study 25447334 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding Health
Number of subjects: 148
Study 25447334 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 148
Study 25447334 — intervention group
Group type: COMPARATOR
Intervention: Control (obesity education video)
Number of subjects: 148
Study 22743161 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent drug users (used illicit drugs other than marijuana and/or nonmedical prescription drugs every year during the first four years)
Number of subjects: 620
Study 22743161 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent drug users and infrequent marijuana users
Number of subjects: 620
Study 22743161 — intervention group
Group type: COMPARATOR
Intervention: Employed full-time individuals
Number of subjects: 620
Study 22743161 — intervention group
Group type: COMPARATOR
Intervention: Employed part-time individuals
Number of subjects: 620
Study 21784403 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 947
Study 21784403 — intervention group
Group type: COMPARATOR
Intervention: Nonexclusive breastfeeding
Number of subjects: 947
Study 21784403 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count less than 200 cells/μL
Number of subjects: 947
Study 19336807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining total knee replacement
Number of subjects: 40
Study 19336807 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilised total knee replacement
Number of subjects: 40
Study 19336807 — intervention group
Group type: COMPARATOR
Intervention: Both types of prosthetic knee with reduced patellofemoral joint
Number of subjects: 40
Study 16951850 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ACP) at a point 6.5 cm above the apex of the auditory pavilion in the parietal region
Number of subjects: 76
Study 16951850 — intervention group
Group type: COMPARATOR
Intervention: Control group acupuncture at a point 3 cm above the ACP point
Number of subjects: 76
Study 14675304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing interventions (specific details not provided)
Number of subjects: 47
Study 10780758 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 1 year
Number of subjects: 80
Study 10780758 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 80
Study 10780758 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 80
Study 9351712 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous arteriovenous rewarming (CAVR)
Number of subjects: 57
Study 9351712 — intervention group
Group type: COMPARATOR
Intervention: Standard rewarming (SR)
Number of subjects: 57
Study 8454808 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 878
Study 8454808 — intervention group
Group type: EXPERIMENTAL
Intervention: Na/K intervention
Number of subjects: 878
Study 8454808 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 878
Study 3022785 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (topically applied in a gel)
Number of subjects: 0
Study 3022785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3022785 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0
Study 31981832 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games (AVGs)
Number of subjects: 80
Study 31981832 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise
Number of subjects: 80
Study 29953567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 1
Number of subjects: 48
Study 29953567 — intervention group
Group type: COMPARATOR
Intervention: Positive control (commercially available denture adhesive cream)
Number of subjects: 48
Study 29953567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 2
Number of subjects: 48
Study 27377292 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training group (STG)
Number of subjects: 45
Study 27377292 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training group (HTG)
Number of subjects: 45
Study 27377292 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study 27377292 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (STG, HTG, CG)
Number of subjects: 45
Study 24141036 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 870
Study 24141036 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 150 mg orally every month
Number of subjects: 870
Study 24141036 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 870
Study 24141036 — intervention group
Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 870
Study 22301925 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy foods with high-normal isoflavones (73 mg/d)
Number of subjects: 85
Study 22301925 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy foods with low isoflavones (10 mg/d)
Number of subjects: 85
Study 22301925 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy foods with prebiotic (10 g polyfructans/d)
Number of subjects: 85
Study 22301925 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy foods with low-carbohydrate diet (26% carbohydrate)
Number of subjects: 85
Study 21211262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of high‐dose pirarubicin during perioperative period
Number of subjects: 120
Study 21211262 — intervention group
Group type: COMPARATOR
Intervention: Intravesical perfusion of pirarubicin performed regularly after operation
Number of subjects: 120
Study 18942602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical technique (rubber cup attached to a low-speed handpiece)
Number of subjects: 10
Study 18942602 — intervention group
Group type: COMPARATOR
Intervention: Manual technique (plastic spatula)
Number of subjects: 10
Study 15611864 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked intramedullary nailing
Number of subjects: 78
Study 15611864 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 78
Study 12796358 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106
Study 12796358 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha/cytarabine
Number of subjects: 1106
Study 10555025 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 224
Study 10555025 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 224
Study 10555025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 8934458 — intervention group
Group type: EXPERIMENTAL
Intervention: Item method of directed forgetting
Number of subjects: 0
Study 8934458 — intervention group
Group type: COMPARATOR
Intervention: List method of directed forgetting
Number of subjects: 0
Study 1653142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100-300 mg oral)
Number of subjects: 5863
Study 1653142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (4-8 mg subcutaneous)
Number of subjects: 5863
Study 1653142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5863
Study 6136437 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting vaginal pessary containing 3.0 mg 15-methyl-PGF2(α) methyl ester
Number of subjects: 1147
Study 6136437 — intervention group
Group type: COMPARATOR
Intervention: Intraamniotic administration of 2.5 mg 15-methyl-PGF2(α)
Number of subjects: 1147
Study 6136437 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting vaginal pessary complemented with intramuscular injections of 15-methyl-PGF2(α) (0.2-0.4 mg every third hour for up to 12 hours)
Number of subjects: 1147
Study 6136437 — intervention group
Group type: COMPARATOR
Intervention: Intraamniotic administration of 15-methyl-PGF2(α)
Number of subjects: 1147
Study 6136437 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pessary
Number of subjects: 1147
Study 31418607 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence message
Number of subjects: 388
Study 31418607 — intervention group
Group type: COMPARATOR
Intervention: Harm reduction message
Number of subjects: 388
Study 31418607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactance (negative cognitive appraisal)
Number of subjects: 388
Study 31418607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactance (anger)
Number of subjects: 388
Study 30247950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extracts (Helixor A, Iscador M Spez) injected three times per week during 18 weeks of chemotherapy
Number of subjects: 95
Study 30247950 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study 26784010 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-CL
Number of subjects: 234
Study 26784010 — intervention group
Group type: COMPARATOR
Intervention: MHE
Number of subjects: 234
Study 25147819 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 14
Study 25147819 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 22848508 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2/ANKK1‐TaqIA A1‐allele status
Number of subjects: 84
Study 22848508 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD4 7R-allele status
Number of subjects: 84